Navigation Links
The Quigley Corporation Reports First Quarter 2009 Results
Date:5/1/2009

loping natural-source potential prescription and other products. Research and development costs associated with Quigley Pharma for the first quarter of 2009 were $248,000 compared to $1.4 million for the first quarter of 2008. This reduction reflects the completion of the Phase IIb clinical study for QR-333 Diabetic Peripheral Neuropathy in November 2008, which reduced R&D investment costs for the first quarter of 2009.

On April 30, 2009, the Company announced that its Diabetic Peripheral Neuropathy Phase IIb clinical study demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR-333. These unexpected positive findings expand the potential for the QR-333 drug for Diabetic Neuropathy and suggest possible disease modification.

No tax provision or benefits to reduce losses are provided for the first quarter of 2009 and 2008, as the Company is in a net operating loss carry-forward position for which a valuation has been established.

The Company continued to invest in pharmaceutical research and development including QR448(a), a veterinary anti-viral compound against Infectious Bronchitis Virus (IBV) in poultry, and QR-333, an investigational new formulation for treating conditions associated with Diabetic Peripheral Neuropathy.

The research by the Company is part of its strategic initiatives to generate future growth. These initiatives include capitalizing on the growth potential of Quigley Pharma by developing natural-source potential prescription products particularly for Diabetic Peripheral Neuropathy, avian flu in animals and for protection against ionizing radiation.

Ongoing Quigley Pharma research and development initiatives include investing in its key pharmaceutical formulations, QR-333. The last subject in the Phase IIb study completed treatment at the end November 2008 and the study is now in the final
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
2. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
3. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
4. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
6. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
9. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
10. Protein Sciences Corporation Appoints New Board of Directors
11. Digirad Corporation Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Laurel, N.J. (PRWEB) July 14, 2014 ... Mount Laurel, has announced the publication of its first military ... plane crash on Black Thursday in October 1943 and 19 ... March to return home and build the American dream. ... II and the American dream (Amazon) is a ...
(Date:7/14/2014)... According to a recent study ... a connection between women with high levels of a ... doctors have theorized about the role stress plays in ... provide scientific support. , “Stress, if very significant, can ... Barmat, an OB/GYN who specializes in reproductive endocrinology and ...
(Date:7/14/2014)... There’s an old adage that says first impressions make ... say the products offered in their preorder event not only ... The Lash Palette for $40,” said Jenelle Paris, founder and ... explained that the first 1,000 have already been sold during ... on to point out that her company is an online ...
(Date:7/14/2014)... Jordan Valley Medical Center is expanding the ... center set to open by the fall of 2015. ... west of I-15 in the Salt Lake Valley providing ... Valley Medical Center has partnered with Elekta, a company ... for radiation therapy, radiosurgery and brachytherapy, to bring Versa ...
(Date:7/14/2014)... For the Spanish Royal Academy, senescent is he who ... the dictionary: not only is senescence not a synonym ... the organism. Cellular senescence is such a badly named ... area think it needs another name. That is the ... Research Centre (CNIO), one of the world,s leading experts ...
Breaking Medicine News(10 mins):Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 3Health News:The Lash Palette Preorder Event Has Officially Begun 2Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3
... diabetes research in India, even though the country remains one ... disease. Indian scientists have published only one percent of the ... Indian Journal of Medical Research, in an assessment of the ... India published a total of 3068 papers during the 30 ...
... 25 million dollar space programme, will carry out scientific ... cells in outer space, reports said Wednesday. ... and the crystallisation of protein, said Abdul Rahman Abdul ... National University of Malaysia. ,"The research is ...
... their health by using over the counter nutritional supplements ... cons with the health professionals managing their conventional treatment. ... Griffith's School of Nursing, says that though some complementary ... have side effects or interact with conventional medications. ...
... School of Medicine in St. Louis, Missouri, have found ... to treatments for deadliest poisons like Ricin, cholera toxin, ... deadly strains of E. coli bacteria, these toxins travel ... Golgi network and endoplasmic reticulum before interrupting protein synthesis. ...
... a developing female sheep foetus to low doses of commonly ... ,The study was conducted by a team ... of Aberdeen, Scotland, UK. ,As part of the ... a cocktail of chemicals and heavy metals in an animal ...
... New research by the British charity Save the Children, shows ... nutritious diet , they would have to spend three times ... reported by The Independent, this would amount to a 1,700 ... research calculated how much a healthy diet, based on local ...
Cached Medicine News:Health News:India's Share in Global Diabetes Research is One Percent 2Health News:Diabetics Risking Health by Using Alternative Medications Without Consultation 2Health News:For Bangladeshis, a Nutritious Diet Would Cost 1,700 Pounds Per Week 2
(Date:7/14/2014)... 14, 2014  GenSpera, Inc. (OTCQB: GNSZ), a ... of cancer, announces that Kareg Corporation,s Director of ... the following research report on  the company. ... of Research, Kareg Corporation, Initiating Coverage with a ... full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ ...
(Date:7/14/2014)... 2014  Otonomy, Inc., a clinical-stage biopharmaceutical company focused ... diseases and disorders of the inner and middle ear, ... statement on Form S-1 with the U.S. Securities and ... offering of shares of its common stock. All shares ... will be offered by Otonomy. The number of shares ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Otonomy Files Registration Statement for Proposed Initial Public Offering 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... YORK, Sept. 21 An eminent international panel of ... LLY ) to receive a World Business and ... successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB). ... of The Lilly MDR-TB Partnership demonstrate a clear linkage ...
... According to Millennium Research Group (MRG), the global authority ... new growth factors, combined with greater variety and improved features ... market to nearly $2.3 billion through 2015. Medtronic ... AMPLIFY , is set to be released in the US ...
Cached Medicine Technology:Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 2Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 3Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 2Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: